IP Verse

Methods For Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan And Oxaliplatin - EP3337478

The patent EP3337478 was granted to Ipsen Biopharm on Aug 12, 2020. The application was originally filed on Aug 19, 2016 under application number EP16758337A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3337478

IPSEN BIOPHARM
Application Number
EP16758337A
Filing Date
Aug 19, 2016
Status
Granted And Under Opposition
Jul 10, 2020
Grant Date
Aug 12, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMay 12, 2021ELKINGTON AND FIFEADMISSIBLE
SANDOZMay 6, 2021KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (1) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS8147867

Non-Patent Literature (NPL) Citations (25) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- A. Dean, Et Al, "A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously", J. Clin. Oncol., (20160101), vol. 34, no. 4, XP055820811-
OPPOSITION- A. DEAN et al., "randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously", J. Clin. Oncol., (20160000), vol. 34, no. 4, XP055820811-
OPPOSITION- D.F. GADDY et al., "Preclinical anti-tumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) + 5-FU + oxaliplatin in pancreatic cancer", Cancer Res, (20160000), vol. 76, no. 14, XP055820818-
OPPOSITION- D.F. Gaddy, Et Al, "Preclinical anti-tumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) + 5-FU + oxaliplatin in pancreatic cancer", Cancer Research, (20160101), XP055820818-
OPPOSITION- D. VON HOFF et al., "NAPOLI-1: RANDOMIZED PHASE 3 STUDY OF MM-398", Ann. Oncol., (20140000), vol. 25, no. 2, pages ii105 - ii117, XP055820798-
OPPOSITION- D. Von Hoff, Et Al, "NAPOLI-1: RANDOMIZED PHASE 3 STUDY OF MM-398", Ann. Oncol., (20140101), vol. 25, no. 2, page i117, XP055820798-
OPPOSITION- Haijun Zhang, "Onivyde for the therapy of multiple solid tumors", Onco Targets Ther, (20160101), vol. 9, pages 3001 - 3007, XP055820813-
OPPOSITION- Hann Byron, Karissa Peth; Donghui Wang; Stephan Gysin; Shang Li; Erika Kullberg; Yun Hom; Matthew Goldman; Margaret Tempero; John Park, "Abstract 5648 - Lipidic nanoparticle CPT-11 in a bioluminescent orthotopic pancreas cancer model ", Cancer research, US , (20070101), vol. 67, no. Suppl 9, ISSN 0008-5472, XP055954201-
OPPOSITION- H. ZHANG et al., "Onivyde for the therapy of multiple solid tumors", Onco Targets Ther, (20160000), vol. 9, pages 30 01 - 3007, XP055820813-
OPPOSITION- J. CARNEVALE et al., "MM-398 (nanoliposomal irinotecan):emergence of a novel therapy for the treatment of advanced pancreatic cancer", Fut. Oncol., (20160000), vol. 12, no. 4, pages 453 - 464, XP055820804-
OPPOSITION- Julia Carnevale, Andrew H Ko, "MM-398 (nanoliposomal irinotecan):emergence of a novel therapy for the treatment of advanced pancreatic cancer", Fut. Oncol., (20160101), vol. 12, no. 4, pages 453 - 464, XP055820804-
OPPOSITION- KO A H ET AL, "A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer", British Journal of Cancer, (20130820), vol. 109, no. 4, ISSN 1532-1827, pages 920 - 925, XP002763721-
OPPOSITION- Mahaseth et al, "Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma", Pancreas, (20131100), vol. 42, no. 8, pages 1311 - 1315-
OPPOSITION- "Onivydeâ„¢", Highlights of Prescribing Information, (20151001), pages 1 - 18, XP055844932-
OPPOSITION- P. PARHI et al., "nanotechnology-based combinationdrug delivery", Drug Discov. Today, (20120000), vol. 17, no. 17,18, page 1044, XP055820822-
OPPOSITION- R.D.W. MARSH et al., "Pancreatic cancer and FOLFIRINOX: a new era and new questions", Cancer Med, (20150000), vol. 4, no. 6, pages 853 - 863, XP055820799-
OPPOSITION- R.D.W. Marsh, Mark S. Talamonti, Matthew Harold Katz & Joseph M. Herman, "Pancreatic cancer and FOLFIRINOX: a new era and new questions", Cancer Med, (20150101), vol. 4, no. 6, pages 853 - 863, XP055820799-
OPPOSITION- Riyambada Parhi, Chandana Mohanty And Sanjeeb Kumar Sahoo, "Nanotechnology-based combinational drug delivery", Drug Discov. Today, (20120101), vol. 17, no. 17-18, pages 1044 - 1052, XP055820822-
OPPOSITION- "Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma", clinicaltrials.gov NCT02551991, (20150915), XP055820797-
OPPOSITION- "Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma", NCT02551991, (20150915), XP055820797-
OPPOSITION- Chang T. C.; Shiah H. S.; Yang C. H.; Yeh K. H.; Cheng A. L.; Shen B. N.; Wang Y. W.; Yeh C. G.; Chiang N. J.; Chang J. Y.; Chen L. T., "Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients", Cancer chemotherapy and pharmacology, DE , (20150111), vol. 75, no. 3, doi:10.1007/s00280-014-2671-x, ISSN 0344-5704, pages 579 - 586, XP035456963
OPPOSITION- Thierry Conroy, Francoise Desseigne, Marc Ychou, Olivier Bouche, Rosine Guimbaud, Yves Becouarn, Antoine Adenis, Jean-Luc Raoul, Sophie Gourgou-Bourgade, Christelle de la Fouchardiere, Jaafar Bennouna, Jean-Baptiste Bachet, Faiza Khemissa-Akouz, Denis Pere-Verge, Catherine Delbaldo, Eric Assenat, Bruno Chauffert, Pierre Michel, Christine Montoto-Grillot, M.Chem., Michel Ducreux, "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer", The New England journal of medicine, US , (20110512), vol. 364, no. 19, doi:10.1056/NEJMoa1011923, ISSN 0028-4793, pages 1817 - 1825, XP002730536
OPPOSITION- D. C. Drummond, C. O. Noble, Z. Guo, K. Hong, J. W. Park, D. B. Kirpotin, "Development of a Highly Active Nanoliposomal Irinotecan Using a Novel Intraliposomal Stabilization Strategy", Cancer research, US , (20060315), vol. 66, no. 6, doi:10.1158/0008-5472.CAN-05-4007, ISSN 0008-5472, pages 3271 - 3277, XP055329486
OPPOSITION- L. Chen, H. Shiah, T. Chao, R. K. Hsieh, G. Chen, J. Chang, G. Yeh, "Phase I study of liposome irinotecan (PEP02) in combination with weekly infusion of 5-FU/LV in advanced solid tumors", Journal of Clinical Oncology, vol. 28, no. 15_Suppl., doi:10.1200/jco.2010.28.15_suppl.e13024, (20100101), URL: http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.e13024, (20161102), XP002763720
OPPOSITION- Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul J L, Boige V, Berille J, Conroy T., "Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.", Journal of Clinical Oncology, US , (20130101), vol. 31, no. 1, doi:10.1200/JCO.2012.44.4869, ISSN 0732-183X, pages 23 - 29, XP002743175

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents